The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

Retrospective data on patients with optic neuritis was recently used to study the prevalence and quality of asymptomatic optic nerve enhancement. The study found that roughly 1 in 6 (17%) inter-attack ...

Please provide your email address to receive an email when new articles are posted on . Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated ...

Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...

Increase in prevalence of optic nerve disorder treatment, growth in geriatric population and increase in technological advancement drive the growth of the global optic nerve disorder treatment market.

Chronic rhinosinusitis (CRS) significantly affects ophthalmologic health but remains largely manageable, according to a ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Stoke Therapeutics (NASDAQ:STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). FALCON is a ...

An OU Health eye specialist explains who is most at risk, why symptoms are rare, and how early exams can prevent permanent ...